Program at a glance


Thursday 21 September, 2017 - 
NKI/AVL, Plesmanlaan 121, Amsterdam

  Nominating comittee meets online
08:30-09:00 ISSTD executive registration and welcome
09:00-11:00 ISSTD executive meeting
10:00-11:00 EOTTD working party registration and welcome
11:00-13:00 EOTTD working parties
13:00-14:00 Lunch
14:00 Departure to Boom Chicago Theater (by bus)

Thursday 21 September, 2017 - Boom Chicago Theater, Rozengracht 117,  Amsterdam

14:30-15:30  Registration and welcoming participants & partners with coffee/tea
15:30-16:30 Key note speakers
 

Welcome by ISSTD President Elect Leon Massuger in temporarily absence of ISSTD President Xiang Yang

Debate "to dose high or not to dose high, that's the question"
Michael Seckl (PPT contra) & Anneke Westermann (PPT pro)

Life Lines
Eva van Kempen - PPT

Medicine and Art in Amsterdam
Hans Trum 

16:30-17:00 Break
17:00-18:00 Show Boom Chicago
18:00-18:30 Drinks
18:30 End – Evening on own
19:00 Executive dinner (for invited guests only)

 Friday 22 September, 2017 - Rode Hoed, Keizersgracht 102, Amsterdam

08:30-09:00 Registration and welcoming participants
09:00-09:45

Plenary session organized by the Turkish Working Party on GTD
Chairs: Mehmet Harma & Sinan Ozalp
09:00-09:15


Epidemiological status of GTD in Turkey: experiences from a transition zone -Middle East to Western World
Sinan Ozalp - PPT
09:15-09:30 

Oxidative stress and hydatidiform mole
Muge Harma - PPT
09:30-09:45


The effects of different chemotherapeutic agents on the JAR and JEG-3 human choriocarcinoma cell line models 
Mehmet Harma - PPT
09:45-10:30

Imaging
Chairs: Ross Berkowitz & Raymond Osborne
09:45-10:00


Significance of Chest Computed Tomography in the Clinical Outcome of Patients with Low-Risk Gestational Trophoblastic Neoplasia
Maria Billones-De Ramos - PPT
10:00-10:15


Should CT scan be recommended for the primary imaging evaluation in the FIGO staging of gestational trophoblastic neoplasm patients?
Yu Cheng - PPT
10:15-10:30


Uterine artery pulsatility index plus serum BMP-9 improves prediction of methotrexate resistance in Gestational Trophoblastic Neoplasia
Kevin Elias - PPT
10:30-11:00 Coffee Break
11:00-12:10

Worldwide referral centers & registries
Chairs: Fay Cagayan & Rafael Cortes-Charry
11:10-11:20

Current Management and treatment outcomes of Gestational Trophoblastic Neoplasia at a Philippine Tertiary Government Hospital
Maria Cagayan - PPT
11:20-11:30


Current survival rate of 651 post-molar gestational trophoblastic neoplasia (PMGTN) cases treated between 2009-2016 in a national reference Centre
Rafael Cortes-Charry - PPT
11:30-11:40

The Danish Trophoblast Database
Lone Sunde - PPT
11:40-11:50


Clinical epidemiology in gestational trophoblastic neoplasia in West Java, Indonesia
Herman Susanto - PPT
11:50-12:00


The Belgian Registry for gestational trophoblastic diseases: curative effect of a second curettage
Aleide Vandewal - PPT
12:00-12:10


Incidence Change of Hydatidiform Mole in Asia and Middle East: Important Role for Sociological Factors
Xingran Wang - PPT
12:10-12:40 Poster Tour I
12:40-13:30 Lunch
13:30-14:30

Genetics & Molecular pathways and clinical implications
Chairs: Vilmos Fulop & Annie Cheung
13:30-13:40


PD-L1 expression in premalignant and malignant trophoblasts from gestational trophoblastic diseases is ubiquitous and independent of clinical outcomes
Pierre Bolze - PPT
13:40-13:50


Novel cases of recurrent hydatidiform mole expand the spectrum of familial recurrent hydatidiform mole
Rosemary Fisher - PPT
13:50-14:00


Targeted Genomic Profiling and PD-L1 expression in Epithelioid Trophoblastic Tumors and Placental Site Trophoblastic Tumors
Neil Horowitz - PPT
14:00-14:10


miRNA-seq reveals distinct miRNA profiles between regressing and progressing cases of complete mole
Lawrence Lin - PPT
14:10-14:20


Genotyping of possible hydatidiform moles may lead to incidental findings of abnormalities with implications for future pregnancies
Shyama Mohan - PPT
14:20-14:30


The Genetics of Recurrent Hydatidiform Moles: New Findings and Lessons from the analysis of 111 patients
Rima Slim - PPT
14:30-15:00 Tea Break
15:00-16:15


Molar Pregnancies - organized by WOG
(gynecologic oncology workgroup The Netherlands)
Chairs: Marianne ten Kate-Booij & Leon Massuger
15:00-15:15


Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia be simplified? A new retrospective analysis from a nationwide data-set
Yalck Eysbouts - PPT
15:15-15:30

Online patient information about Gestational Trophoblastic Diseases & the TROPHY-study
Minke Frijstein - PPT
15:30-15:45

New Dutch regression curve
Teun van Herwaarden - PPT
15:45-16:00


Early prediction of post-molar gestational trophoblastic neoplasia with the use of a single serum human chorionic gonadotropin measurement
Yalck Eysbouts 
16:00-16:15 Discussion
16:15-17:05

Pathology
Chairs: Sophie Patrier & Frederic Goffin
16:15-16:25

Clinical outcomes of partial hydatidiform mole in a post- p57 era
Michelle Davis - PPT
16:25-16:35


Central pathology review for gestational trophoblastic diseases: the experience of the Belgian registry in 344 patients
Frederic Goffin - PPT
16:35-16:45

N-acetylglucosaminyltransferase IVa promotes invasion of choriocarcinoma
Kimihiro Nishino - PPT
16:45-16:55


Intraplacental choriocarcinoma arising during a normal pregnancy, in a patient with a previous complete mole: Identification of the causative pregnancy by molecular genotyping
Sophie Patrier - PPT
16:55-17:05 Discussion
17:05 End – Evening on own

 

Saturday 23 September, 2017 - Rode Hoed

08:30-09:00  Welcoming participants
09:00-10:15

Plenary session organized by EOTTD
Chairs: John Tidy & Giorgia Mangili
09:00-09:15

Immunologic Pathways and treatment in GTN 
Michael Seckl - PTT
09:15-09:30

Is chemotherapy always needed for choriocarcinoma management?
Pierre-Adrien Bolze - PTT
09:30-09:45

Report on EOTTD outreach/teaching sessions
Leon Massuger - PTT
09:45-10:00

Setting up an Irish GTD Center 
John Coulter - PPT
10:00-10:15



Does body surface area effect the response to treatment with flat-fixed dose intramuscular methotrexate for low risk Gestational Trophoblastic Neoplasia (GTN)?
Kaveetha Kandiah - PPT
10:15-10:45 Break
10:45-11:25

HCG
Chairs: Fred Sweep & Richard Harvey
10:45-10:55



Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
Antonio Braga - PPT
10:55-11:05


Persistent Real Low-level of Human Chorionic Gonadotropin: Clinical Analysis and Treatment Recommendation
Fengzhi Feng - PPT
11:05-11:15



Does post-pregnancy human chorionic gonadotrophin (hCG) testing identify patients with recurrent gestational trophoblastic disease (GTD)? A national retrospective health care evaluation
Kate Earp - PPT
11:25-12:25

Molar disease
Chairs: Andrea Garret & Greg Robertson
11:25-11:35


One year of short partial mole follow-up in a UK GTD centre – who did we review and what difference did it make?
Annie Hills - PPT
11:35-11:45


Systematic histology review of 1521 cases referred to tertiary referral centre- a changing pattern?
Baljeet Kaur - PPT
11:45-11:55


Hydatidiform mole: Accuracy of the Danish National Patient Registry, the Danish Cancer Registry, and the Danish Pathology Registry 1999-2010
Helle Lund - PPT
11:55-12:05


WHO Prognostic classification system for Gestational Trophoblastic Neoplasia – can we do better?
Victoria Parker - represented by Matt Winter - PPT
12:05-12:15


The influence and evaluation of lung metastasis on the outcome of patients in gestational trophoblastic neoplasia - a 10 years' study in a single institute 
Hailin Yu - PPT
12:15-12:25 Discussion
12:25-13:30 Lunch
13:30-14:00 Poster Tour II
14:00-15:30

Low-risk GTN
Chairs: Francois Golfier & Antonio Braga
14:00-14:15

Second curettage in low risk gestational trophoblastic neoplasia
Ray Osborne - PPT
14:15-14:30



The Impact of Uterine Re-curettage on the Number of Chemotherapy Courses in Treatment of Post Molar Gestational Trophoblastic Neoplasia. A Randomized – Controlled Study
Reda Hemida - PPT
14:30-14:45



Efficacy and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: the New England Trophoblastic Disease Center experience
Izildinha Maesta - PPT
14:45-15:00


Prevalence and factors associated with hydatidiform mole among patients undergoing uterine evacuation 
Olivier Mulisya - PPT
15:00-15:15



TA Phase III Randomized Trial of Pulse Actinomycin-D versus Multi-day Methotrexate for the Treatment of Low Risk Gestational Trophoblastic Neoplasia
Julian Schink - PPT
15:15-15:30





Can increasing the hCG cut-off from 300 IU/L to 1000 IU/L for starting actinomycin D (ActD) in low risk (LR) patients with post-molar gestational trophoblastic neoplasia (GTN) developing resistance to methotrexate and folinic acid (MTX/FA), spare more women multi-agent chemotherapy without compromising outcomes?
Michael Seckl - PPT
15:30-15:45 Discussion
15:45 End
16:00-17:00 Boattour through Amsterdam
18:15-22:30 Social evening and dinner in Koepelkerk

 

Sunday 24 September, 2017 - Rode Hoed

08:30 Welcoming participants
09:00-10:30

High-risk GTN
Chairs: Hideo Matsui & Michael Seckl
09:00-09:10




Paclitaxel and Etoposide alternating with Paclitaxel and Cisplatin (TE/TP) as a salvage chemotherapy for gestational trophoblastic neoplasia (GTN) relapsed or refractory to Etoposide, Methotrexate and Actinomycin D alternating with Cyclophosphamide and Vincristine (EMA/CO)
Preetha Aravind - PTT
09:10-09:20


The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia
Minke Frijstein by Michael Seckl - PTT
09:20-09:30


Gestational trophoblastic neoplasia with brain metastasis at diagnosis: a retrospective cohort study
François Golfier - PTT
09:30-09:40



Use of Granulocyte Colony Stimulating Factors (G-CSFs) with Multiagent Chemotherapy for High-Risk Gestational Trophoblastic Neoplasia (GTN) Decreases Neutropenic Complications and Treatment Delays
John Lurain - PTT
09:40-09:50


The role of Central Nervous System Chemoprophylaxis in the treatment of Gestational Trophoblastic Neoplasia: a single center experience
Naveed Sarwar - PTT
09:50-10:00


Comparison of toxicities between MEA and EMA-CO regimens as first line treatment of high-risk GTN
Kam Singh - PPT
10:00-10:10

Choriocarcinoma Associated with Term Pregnancy
Anna Strohl - PPT
10:10-10:20


Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: a retrospective cohort study
Yang Xiang - PPT
10:20-10:30


Efficacy and side effects of FAEV regimen and EMA/CO regimen as primary treatment for high-risk gestational trophoblastic neoplasia
Jun Zhao - PPT
10:30-11:00 Coffee break
11:00-12:00

ETT&PSTT
Chairs: Matt Winter & Hextan Ngan
11:10-11:20



Identification of new prognostic factors for placental-site and epithelioid trophoblastic tumours (PSTT/ETT): platinum-based intensive chemotherapy improves survival in poor risk patients
Fieke Froeling by Michael Seckl - PPT
11:20-11:30


Single center experience in the management of Epithelioid Trophoblastic Tumor
Lawrence Lin - PPT
11:30-11:40


The Demographics, Natural History and Treatment Outcome of Gestational Choriocarcinoma
Philip Savage - PPT
11:40-11:50


Surgery and Platinum/Etoposide-Based Chemotherapy for the Treatment of Epithelioid Trophoblastic Tumor
Janelle Sobecki-Rausch - PPT
11:50-12:00



Ultra high-risk gestational trophoblastic neoplasia (UHR GTN) and placental site/epithelioid trophoblastic tumours (PSTT/ETTs): an international collaborative database project
Matt Winter - PPT
12:00-12:30 Poster Tour III
12:30-13:30 Lunch
13:30-14:20

Social aspects of GTN
Chairs: John Lurain & Leon Massuger
13:30-13:40



Provincial GTD / GTN Registry: Patients and Healthcare Providers’ Satisfaction
It is insufficient to simply inform patients with trophoblastic diseases: they want to be accompanied
Magali Breguet - PPT
13:50-14:00


Gestational Trophoblastic Disease Electronic Consults: What do Patients and Physicians Want to Know?
Roni Nitecki - PPT
14:00-14:10



The Role of Nurse Clinicians and Advanced Practice Providers in the Management of Supportive Oncology Needs and Treatment-Related Side Effects for Women with Gestational Trophoblastic Neoplasia (GTN)
Karen Novak - PPT
14:10-14:20


Gestational trophoblastic desease: reproductive performance on following pregnancy - an 19 years analysis in a reference center
Elza Uberti - PPT
14:20-15:40 Treatment
Chairs: John Coulter & Xiang Yiang
14:20-14:30


Efficacy and toxicity of second-line 5-day dactinomycin in methoresistant GTN patients
Pierre-Adrien Bolze - PPT
14:30-14:40


Cyclin dependent kinases 4 and 6 (CDK4/6) as a potential new therapeutic target in drug-resistant gestational trophoblastic neoplasia (GTN)
Marina Georgiou - PPT
14:40-14:50


Pembrolizumab induces long term complete remission of chemotherapy resistant gestational trophoblastic neoplasia (GTN)
Ehsan Ghorani - PPT
14:50-15:00



Decentralized treatment for post-molar gestational trophoblastic neoplasia (PMGTN) is associated with increased lines of chemotherapy and longer time to remission
Whitfield Growdon by Elisabeth Diver - PPT
15:00-15:30 Tea break
15:30-15:40


The Efficacy and Safety of Different Chemotherapy Regimens in Low-risk Gestational Trophoblastic Neoplasia: A Network Meta-analysis 
Jun Li - PPT
15:40-15:50


First-line hysterectomy for women no longer wishing to conceive with low-risk gestational trophoblastic neoplasia
Jérôme Massardier - PPT
15:50-16:00


Gestational Trophoblastic Neoplasia Located in the Cesarean Scar: A review of 31 cases and their implications for diagnosis and treatments
Junjun Yang - PPT
16:00-16:10



TROPHIMMUN, a phase II trial of the anti-PDL1 monoclonal antibody avelumab in chemo-resistant gestational trophoblastic neoplasia patients: preliminary results
Benoit You 
16:10-16:30 General Assembly
16:30-17:00 Closing Ceremony and Awards 
17:00 End of XIX World Congress of Gestational Trophoblastic Diseases